Along with the known prognostic factors, including the extent of resection, MGMT promoter methylation status, and standard radiochemotherapy, we suggested that awake resection was an independent predictor of progression-free and overall survivals in IDH-wildtype glioblastoma patients, both in the whole series, after case matching, and in the subgroup of 223 patients operated on by the two neurosurgeons expert both in awake and asleep surgery. This evidence concerns the gene IDH1 and glioblastoma.